IFNA1 and neoplasm: The rationale was to combine tumor cell death induced by the chemotherapeutic agent with the phagocytic activity and T-cell stimulatory properties of IFN-DCs, therefore aiming at an in vivo loading of DCs with patient specific tumor associated antigens.